Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Dupilumab's Real-World impact on swallowing and quality of life

NCT ID NCT06695897

Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study follows 150 adults with eosinophilic esophagitis (EoE) who are starting dupilumab as part of their normal care. Researchers will collect information on medical history, symptoms, and quality of life over two years to see how well the treatment works in real-world settings. The goal is to better understand long-term safety and effectiveness outside of a controlled clinical trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering from EoE, ≥ 12 years of age with at least 40 kg bodyweight who are planned to be initiated with dupilumab for the treatment of EoE according to the prescribing information, i.e., the current Summary of Product Characteristics approved in the European Union (EU-SmPC).

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with EoE who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy * Patients for whom the treating physician has decided to initiate new treatment with dupilumab for EoE according to EU-SmPC independently from entry in study or for whom treatment with dupilumab for EoE according to EU-SmPC has been started within the last 7 days. The decision to initiate dupilumab treatment is made by the treating physician and the patient according to the patients' medical need and to the standard of best medical practice. This decision is made independently and before inclusion in this NIS. * ≥ 12 years of age at baseline visit * ≥ 40 kg bodyweight * Voluntary study participation and signed written informed consent by patient and parent(s)/guardian(s), if applicable Exclusion Criteria: * Patients who have a contraindication to dupilumab according to the current EU-SmPC. * Patients who have been treated with dupilumab for more than 7 days * Any acute or chronic condition that, in the treating physician's opinion, would limit the patients' ability to complete questionnaires or to participate in this study or impact the interpretation of the results. * Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study (parallel inclusion in another Sanofi-independent registry might be possible if the patient gives consent) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eosinophilic esophagitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eosinophilic esophagitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    15 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number: 0000001

    RECRUITING

    Dachau, Bavaria, 85221, Germany

  • Investigational Site Number: 0000002

    RECRUITING

    Weyhe-Kirchweyhe, Lower Saxony, 28844, Germany

  • Investigational Site Number: 0000003

    RECRUITING

    Burbach, North Rhine-Westphalia, 57299, Germany

  • Investigational Site Number: 0000004

    RECRUITING

    Berlin, 10409, Germany

  • Investigational Site Number: 0000005

    RECRUITING

    Giessen, Hesse, 35392, Germany

  • Investigational Site Number: 0000006

    RECRUITING

    Guelders, North Rhine-Westphalia, 47608, Germany

  • Investigational Site Number: 0000007

    RECRUITING

    Bochum, North Rhine-Westphalia, 44791, Germany

  • Investigational Site Number: 0000008

    RECRUITING

    Leipzig, Saxony, 4103, Germany

  • Investigational Site Number: 0000009

    RECRUITING

    Aschaffenburg, Bavaria, 63739, Germany

  • Investigational Site Number: 0000010

    RECRUITING

    Münster, North Rhine-Westphalia, 48143, Germany

  • Investigational Site Number: 0000011

    RECRUITING

    Wetzlar, Hesse, 35578, Germany

  • Investigational Site Number: 0000012

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

  • Investigational Site Number: 0000013

    RECRUITING

    Osnabrück, Lower Saxony, 49074, Germany

  • Investigational Site Number: 0000014

    RECRUITING

    Augsburg, Bavaria, 86154, Germany

  • Investigational Site Number: 0000015

    RECRUITING

    Magdeburg, Saxony-Anhalt, 39130, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.